CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Canada

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Canada

  • July 2017 •
  • 228 pages •
  • Report ID: 5057905 •
  • Format: PDF
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Canada

Summary
Canada is a mature healthcare market, with a strong focus on pharma R&D and a high level of total healthcare expenditure that is 11% of its Gross Domestic Product (GDP). The increasing elderly population and its associated disease burden are expected to drive the growth of the pharmaceutical market, while government initiatives to reduce healthcare expenditure may limit growth. The value of the Canadian pharmaceutical market increased from US$19.6 Billion in 2009 to US$22.6 Billion in 2016, at a Compound Annual Growth Rate (CAGR) of 2%. The market value is expected to reach US$25 Billion in 2021.

In 2016, the value of the generic pharmaceutical market was US$6.16 Billion. In 2016, generic drugs accounted for 70.2% of prescriptions in Canada, compared with 89% in the US. However, generic drug sales account for only 22.4% of the US$25.1 Billion pharmaceutical market. The use of generic medicines saved nearly US$20 Billion for the government in 2016. The generics market is expected to continue to grow as the government promotes generics usage and as quality perception improves among patients.

In 2016 healthcare expenditure in Canada stood at US$228.1 Billion, an increase of US$44.8 Billion from 2015. In 2009, the healthcare expenditure as a percentage of GDP was 11.6%, which decreased to an estimated 11.1% in 2016. In 2009, health expenditure per capita was approximately US$4,497, which increased to an estimated US$6,299 in 2016. The increasingly elderly population and associated disease burden have been driving the growth of the pharmaceutical market. In 2016, the elderly population accounted for 17% of the total population, and this is expected to increase at a CAGR of 3.7% to 20% by 2021.

Canadian medical device market was valued at US$8.6 Billion in 2009, which increased to US$10.5 Billion in 2016, and it is expected to grow at a CAGR of 4.2% from US$11.4 Billion in 2017 to US$13.4 Billion in 2021. The main segments were ophthalmic devices, orthopedic devices, drug delivery devices, in vitro diagnostics and healthcare IT.

The report "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Canada" is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Canada.

In particular, this report provides the following analysis -
- Provides an overview of the Canadian healthcare market and its key driving factors. It also gives a snapshot of the demographic, regulatory, and reimbursement landscape and healthcare infrastructure in Canada.
- Provides an overview of the Canadian pharmaceutical and medical device markets, covering market size; the market shares of generic, Over-the-Counter (OTC) and biologic/biosimilar products; and the key drivers and barriers for the overall market. It also includes profiles of the major players, as well as SWOT assessments.
- Covers the reimbursement and payer landscape, and includes details of the reimbursement process, insurance providers, pricing policies and drug price trends in Canada.
- Provides detailed analysis of the political and economic environment in Canada, and analyses economic indicators, demographics, and healthcare infrastructure and expenditure.
- Provides an overview of the opportunities for and challenges to growth in the Canadian healthcare market.

Companies mentioned in this report: Johnson & Johnson, Novartis, Teva, Apotex, Gilead.

Scope
The report provides information on the healthcare, regulatory, and reimbursement landscape in Canada, and includes -
- An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
- Profiles and SWOT analyses of the major players in the pharmaceutical market (Johnson & Johnson, Novartis, Teva, Apotex and Gilead) and profiles and SWOT analyses of the major players in the medical device market (Johnson & Johnson, Medtronic, Baxter, Fresenius and Sonova)
- An insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices
- Detailed analysis of the political and economic environment, covering economic indicators, demographics, healthcare infrastructure and healthcare expenditure
- An overview of the opportunities for and challenges to growth in the Canadian healthcare market

Reasons to buy
This report will enhance your decision-making capability by allowing you to -
- Develop business strategies by understanding the trends shaping and driving the Canadian healthcare market
- Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact the healthcare market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
- Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership
- Identify, understand, and capitalize on the opportunities and challenges in the Canadian healthcare market
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.